DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Treanda (Bendamustine Hydrochloride) - Published Studies

 
 



Treanda Related Published Studies

Well-designed clinical trials related to Treanda (Bendamustine)

Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. [2011.01]

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. [2009.09.10]

Phase II STUdy with 3rd- or 4th-line bendamustine (flat dose) therapy in patients with metastatic breast cancer. [2009.09]

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). [2006.04]

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). [2006.02]

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. [2005.09]

Bendamustine in the treatment of multiple myeloma: results and future perspectives. [2002.08]

[Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil] [1998]

Other research related to Treanda (Bendamustine)

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. [2014]

Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. [2014]

Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma. [2012]

Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. [2012]

Salvage therapy with single agent bendamustine for recurrent glioblastoma. [2011.12]

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. [2011.09.10]

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. [2011.09.01]

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. [2011.09]

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. [2011.05]

Conclusion and future directions. [2011.04]

Bendamustine's emerging role in the management of lymphoid malignancies. [2011.04]

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. [2011.03.10]

Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. [2011.02]

Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study. [2011.02]

Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab. [2011]

Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. [2011]

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. [2010.11]

Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. [2010.09.10]

Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. [2010.09]

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. [2010.09]

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. [2010.09]

Bendamustine: something old, something new. [2010.08]

Severe cutaneous interface drug eruption associated with bendamustine. [2010.07.15]

Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. [2010.05.01]

Bendamustine: new perspective for an old drug in lymphoproliferative disorders. [2010.04]

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. [2010.02]

Bendamustine in patients with relapsed or refractory multiple myeloma. [2010.01.29]

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. [2010.01.01]

Bendamustine: a new treatment option for chronic lymphocytic leukemia. [2009.11]

Bendamustine-associated hemolytic anemia. [2009.11]

Bendamustine therapy in chronic lymphocytic leukemia. [2009.07]

Bendamustine hydrochloride - a renaissance of alkylating strategies in anticancer medicine. [2009.06]

Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. [2009.04]

Bendamustine: rebirth of an old drug. [2009.03.20]

Role of bendamustine in the treatment of chronic lymphocytic leukemia. [2009.02.18]

Bendamustine: a new look at an old drug. [2009.02.01]

Bendamustine in the treatment of chronic lymphocytic leukemia. [2009.02]

Identification and quantitation of the N-acetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. [2009.02]

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. [2009]

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. [2008.11.01]

Bendamustine: a novel cytotoxic agent for hematologic malignancies. [2008.10]

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. [2008.10]

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. [2008.09.20]

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. [2008.08.24]

Bendamustine in chronic lymphocytic leukemia and refractory lymphoma. [2008.07]

Bendamustine as a model for the activity of alkylating agents. [2008.06]

Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. [2008.05]

Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine. [2008.04]

Bendamustine--a new approach to the treatment of advanced hepatocellular carcinoma? [2008.02]

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. [2008.01.10]

Nilotinib. [2008]

Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War. [2007.12]

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. [2007.12]

Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine. [2007.12]

Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. [2007.09]

Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). [2007.08.15]

A pilot study of bendamustine in advanced bile duct cancer. [2007.07]

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). [2007.07]

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. [2007.06.04]

A pilot study of bendamustine in elderly patients with high-risk MDS and AML. [2007.06]

A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. [2007.06]

Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. [2007.05]

Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. [2007.04]

Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck. [2007.03]

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. [2007.01]

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. [2006.02]

Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. [2005.10]

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. [2005.05.20]

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. [2004.12]

A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma. [2004.12]

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). [2004.09]

Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. [2004.05]

Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. [2003.05]

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. [2002.11]

In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. [2002.10]

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. [2002.08]

Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives. [2002.08]

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. [2002.08]

Phase I studies with bendamustine: an update. [2002.08]

Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. [2002.08]

Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. [2002.05]

Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. [2002.02]

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. [2001.10]

Other possibly related research studies

Multiple myeloma: novel approaches for relapsed disease. [2007.12]

Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies. [2007.12]

First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. [2007.09]

Diagnosis and management of lymphoma. [2006.07]

Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. [2005.12]

Advances in chemotherapy for chronic lymphocytic leukemia. [2004.07]

Hematologic malignancies: new developments and future treatments. [2002.08]

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. [2002.01]

Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. [2008.08]

Considerations with newer regimens for indolent non-Hodgkin lymphoma. [2008.08]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017